CMML highlights from ASH 2022

(56)

Insights into the diagnosis and prognosis of CMML

(2:18)

An insight into the mutational landscape and unique features of CMML

(1:8)

CMML: unmet needs and future outlooks

(1:10)

Diagnosis and management of CMML

(3:5)

Chronic myelomonocytic leukemia patient shares why she feels safe at MD Anderson during COVID-19

(1:53)

Selecting patients with CMML for alloSCT

(1:9)

The need to identify new treatment strategies in CMML \u0026 the potential of targeting inflammation

(2:3)

How do I diagnose chronic myelomonocytic leukemia (CMML)?

(3:36)

William E. Bradbury - Chronic Myelomonocytic Leukemia

(1:26)

Management of CMML

(25:52)

Lenzilumab and azacitidine in proliferative CMML: insights from the PREACH-M study

(2:28)

Epigenetic dysregulation in ASXL-1-mutant CMML

(1:47)

Safety and efficacy of ASTX727 in patients with CMML from Phase II and Phase III ASCERTAIN studies

(2:15)

Dr. Mrinal Patnaik of #mayoclinic #CMML Recognizes #rarediseaseday

(48)

Emerging treatments under investigation for CMML

(1:49)

Phase II efficacy and safety results of ruxolitinib for patients with symptomatic CMML

(1:32)

Treatment of CMML Including RAS Mutated - R Itzykson

(28:25)

Diagnosis and Therapy of CMML in 2015

(21:59)

Decitabine vs hydroxyurea for advanced proliferative CMML

(3:55)